Vicore Pharma's drug candidate C21 dilates peripheral resistance vessels in fibrotic disease

Corporate Breaking News

Home : Vicore Pharma's drug candidate C21 dilates peripheral resistance vessels in fibrotic disease

Mar 11 2021	Vicore Pharma's drug candidate C21 dilates peripheral resistance vessels in fibrotic disease
GOTHENBURG, Sweden, March 11, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ), a pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fibrosis (IPF), today announces top line data from a phase II study of its oral angiotensin...


Source:https://www.prnewswire.com:443/news-releases/vicore-pharmas-drug-candidate-c21-dilates-peripheral-resistance-vessels-in-fibrotic-disease-301245265.html

Related News
» Ms. T. Lane’s Latest Release is Sure to Drive Finance Execs Crazy » FinVolution Group Announces Dividend of US$ 0.17 per American Depositary Share for Fiscal Year 2020